The cell-free fetal DNA fraction in maternal blood decreases after physical activity

2014 ◽  
Vol 34 (4) ◽  
pp. 341-344 ◽  
Author(s):  
Jacob Mørup Schlütter ◽  
Lotte Hatt ◽  
Cathrine Bach ◽  
Ida Kirkegaard ◽  
Steen Kølvraa ◽  
...  
Keyword(s):  
Physical Activity ◽  
Maternal Blood ◽  
Fetal Dna ◽  
Cell Free Fetal Dna

Examination of Fetal Cells and Cell-Free Fetal DNA in Maternal Blood for Fetal Gender Determination

2004 ◽  
Vol 58 (1) ◽  
pp. 57-60 ◽  
Author(s):  
Xiao Xi Zhao ◽  
Nobuhiro Suzumori ◽  
Yasuhiko Ozaki ◽  
Takeshi Sato ◽  
Kaoru Suzumori
Keyword(s):  
Maternal Blood ◽  
Gender Determination ◽  
Fetal Cells ◽  
Fetal Dna ◽  
Fetal Gender ◽  
Cell Free Fetal Dna

scholarly journals Fetal Sex Determination Using Cell-Free Fetal Dna (cffDNA) in Maternal Blood

2016 ◽  
Vol 5 (2) ◽  
pp. 89 ◽  
Author(s):  
I Nyoman Hariyasa Sanjaya ◽  
Tjok Gde Agung Suwardewa ◽  
I G Kamasan N. Arijana
Keyword(s):  
Sex Determination ◽  
Maternal Blood ◽  
Fetal Sex ◽  
Fetal Dna ◽  
Cell Free Fetal Dna

Zellfreie fetale DNA im mütterlichen Blut: neue Möglichkeiten in der pränatalen Diagnostik/Cell free fetal DNA in maternal blood: new possibilities in prenatal diagnosis

2012 ◽  
Vol 36 (5) ◽  
Author(s):  
Markus Stumm ◽  
Rolf-Dieter Wegner ◽  
Wera Hofmann
Keyword(s):  
Prenatal Diagnosis ◽  
Next Generation Sequencing ◽  
De Novo ◽  
Maternal Blood ◽  
Fetal Dna ◽  
Cell Free Fetal Dna ◽  
Next Generation Sequencing Ngs ◽  
Fetale Dna ◽  
Generation Sequencing ◽  
Zellfreie Fetale Dna

ZusammenfassungDie zellfreie fetale DNA (cff-DNA) im mütterlichen Blut bietet viele neue Möglichkeiten der pränatalen genetischen Diagnostik. Im Gegensatz zu den etablierten invasiven Techniken der Chorionzottenbiopsie (CVS) und der Amniozentese (AC), die beide mit einem spezifischen Risiko (0,5–1%) einer eingriffsbedingten Fehlgeburt einhergehen, ist die Grundlage für die Gewinnung der cff-DNA eine einfache venöse Blutentnahme der Mutter, die keinerlei Risiko für den Embryo oder Feten darstellt. Damit bietet die cff-DNA die Möglichkeit einer risikofreien genetischen Diagnostik von bestehenden Schwangerschaften. Molekulargenetische Techniken werden schon seit längerer Zeit zum qualitativen Nachweis von spezifischen fetalen Sequenzen, wie paternal vererbten oder neu entstandenen (de novo) Mutationen, eingesetzt. Durch den Einsatz digitaler PCR und Next-Generation-Sequencing (NGS) Technologien gelingt mittlerweile aber auch der sichere quantitative Nachweis von mutierten Allelen sowie von klinisch relevanten Aneuploidien (Trisomie 13, 18 und 21) aus fetaler DNA im mütterlichen Blut.

Progress in prenatal genetic diagnosis: Using cell-free fetal DNA in maternal blood

2013 ◽  
Vol 21 (2) ◽  
pp. 84-90 ◽  
Author(s):  
Kerry Oxenford ◽  
Madhavi Karunaratna ◽  
Melissa Hill ◽  
Sally Taffinder ◽  
Professor Lyn Chitty
Keyword(s):  
Genetic Diagnosis ◽  
Maternal Blood ◽  
Fetal Dna ◽  
Prenatal Genetic Diagnosis ◽  
Cell Free Fetal Dna

scholarly journals Fetal Nucleic Acids in Maternal Circulation: A Genetic Resource for Noninvasive Prenatal Diagnosis

ISRN Genetics ◽  
2013 ◽  
Vol 2013 ◽  
pp. 1-10
Author(s):  
Monisha Banerjee ◽  
Deepika Misra
Keyword(s):  
Prenatal Diagnosis ◽  
Chromosomal Abnormalities ◽  
Quantitative Polymerase Chain Reaction ◽  
Maternal Blood ◽  
Maternal Plasma ◽  
Current Status ◽  
Screening Methods ◽  
Maternal Circulation ◽  
Fetal Dna ◽  
Cell Free Fetal Dna

Invasive prenatal diagnosis (PND) holds a multitude of psychological considerations for women, their partners, family and community as a whole. Earlier, the non-invasive screening methods for certain disorders were serum analytes or ultrasound with low sensitivity and high false positivity. The discovery of fetal DNA in maternal plasma has opened up an approach for noninvasive PND (NIPD). Presence of fetal cells and cell-free fetal DNA (cffDNA) in the blood of pregnant women has been accepted universally and constant efforts are being made to enrich fetal DNA from maternal blood/plasma. Real-time quantitative polymerase chain reaction (qrt-PCR) has enabled fetal DNA to serve as a marker for chromosomal abnormalities, for example, trisomy 21, preterm labor, and preeclampsia. In India, PND is provided in few centers since invasive methods require trained gynecologists, this limits investigation and therefore NIPD with cffDNA from mother's blood will revolutionize fetal medicine. The present paper deals with the latest developments in procurement of cffDNA, the probable source and enrichment of fetal DNA in maternal plasma, and the current status of its detection methodologies, applications, and its potential to be used as a powerful diagnostic tool.

Cell-Free Fetal DNA in Maternal Blood

JAMA ◽  
2004 ◽  
Vol 291 (9) ◽  
pp. 1135 ◽  
Author(s):  
Joe Leigh Simpson ◽  
Farideh Bischoff
Keyword(s):  
Maternal Blood ◽  
Fetal Dna ◽  
Cell Free Fetal Dna
Sign in / Sign up

Export Citation Format

Share Document